Clinical trials: Advanced Digestive System Tumor
Solid Tumor
KN035 for dMMR/MSI-H Advanced Solid Tumors
In this study, patients with previously-treated locally-advanced or metastatic mismatched repair deficient (dMMR) or microsatellite instability-high (MSI-H) colorectal carcinoma (CRC) and other solid tumors will be treated with…
- Trial name
- NCT03667170
- Testing
- KN035
- Where
- 27 sites in China
- Volunteers
- 188 people
- Sponsor
- 3D Medicines (Sichuan) Co., Ltd.
Hepatocellular Carcinoma
Erlotinib in Combination With Docetaxel in Advanced Hepatocellular and Biliary Tract Carcinomas
An unmet medical need exists for the successful therapy of patients with advanced hepatocellular and biliary tract malignances, with few and short lived disease responses to chemotherapy for both advanced stage hepatic and…
- Trial name
- NCT00532441
- Testing
- Erlotinib, Docetaxel
- Where
- 12 sites in United States
- Volunteers
- 25 people
- Sponsor
- Gabi Chiorean, MD
Anal Cancer, HPV-Related Carcinoma
ctHPVDNA Response-Adapted Chemoradiation +/- Retifanlimab Treatment in Locally-Advanced Anal Cancer
This study is for people who have anal cancer and have not yet had treatment. The regular treatment for people who have anal cancer is chemoradiation therapy (CRT).
- Conditions
- Anal Cancer, HPV-Related Carcinoma, Squamous Cell Carcinoma of the Anus
- Trial name
- CHART-AC (NCT07425054)
- Testing
- HPV ctDNA Response based radiation, Chemotherapy, Retifanlimab
- Where
- 2 sites in United States
- Volunteers
- 33 people
- Sponsor
- Jennifer Dorth
Cancer
Intravenous VEGF Trap in Treating Patients With Relapsed or Refractory Advanced Solid Tumors or Non-Hodgkin's Lymphoma
RATIONALE: VEGF Trap may stop the growth of solid tumors or non-Hodgkin's lymphoma by stopping blood flow to the tumor. PURPOSE: This phase I trial is studying the side effects and best dose of intravenous VEGF Trap in treating…
- Trial name
- NCT00083213
- Testing
- ziv-aflibercept
- Where
- United States
- Volunteers
- 25 people
- Sponsor
- Regeneron Pharmaceuticals
Pancreatic Cancer
Phase 1-2 Vatalanib and Gemcitabine in Advanced Pancreatic Cancer
The purpose of the study is to determine the optimal safe and tolerable dose of gemcitabine in combination with once daily or twice daily dose of PTK/ZK in patients with unresectable pancreatic cancer.
- Trial name
- NCT00185588
- Testing
- Vatalanib, Gemcitabine
- Where
- United States
- Volunteers
- 33 people
- Sponsor
- George Albert Fisher
Colorectal Cancer, Colorectal Neoplasms
Diagnostic Accuracy of a Panel of Bacterial Gene Markers (M3) for Colorectal Advanced Neoplasia
The investigators aim to evaluate and compare the diagnostic accuracy of FIT and the novel panel of bacterial gene markers (Fn, m3, Ch and Bc) collectively named as M3, in detecting colorectal advanced neoplasia.
- Conditions
- Colorectal Cancer, Colorectal Neoplasms, Colorectal Adenoma
- Trial name
- M3-PRO (NCT05405673)
- Testing
- Fecal immunochemical test (FIT)
- Where
- Hong Kong
- Volunteers
- 2,500 people, healthy volunteers welcome
- Sponsor
- Chinese University of Hong Kong
Solid Tumor
A Study of Gene Edited Autologous Neoantigen Targeted TCR T Cells With or Without Anti-PD-1 in Patients With Solid Tumors
This is a first in human, single arm, open label, Phase 1a/1b study to determine the safety, feasibility, and efficacy of a single dose of NeoTCR-P1 T cells in participants with solid tumors.
- Trial name
- NCT03970382
- Testing
- NeoTCR-P1 adoptive cell therapy, nivolumab, IL-2
- Where
- 9 sites in United States
- Volunteers
- 21 people
- Sponsor
- PACT Pharma, Inc.
Hepatic Neoplasm Malignant
Oxaliplatin and Capecitabine on Top of Sorafenib Versus Sorafenib Alone in Advanced Hepatocellular Carcinoma Patients
Primary Objective: To evaluate the efficacy of SECOX regimen by adding oxaliplatin plus capecitabine to sorafenib versus sorafenib alone as palliative treatment for unresectable HCC patients to prolong overall survival (OS) for…
- Trial name
- SECOX (NCT01245582)
- Testing
- oxaliplatin (SR96669), capecitabine, sorafenib
- Sponsor
- Sanofi
Esophageal Squamous Cell Carcinoma
Anlotinib Combined With TQB2450 (PD-L1 Inhibitor) in the Treatment of Advanced Esophageal Squamous Cell Carcinoma(ESCC)
To evaluate the effectiveness and safety of anlotinib combined with TQB2450 (PD-L1 inhibitor) in the first-line treatment of patients with advanced ESCC.
- Trial name
- NCT05038813
- Testing
- Anlotinib+TQB2450
- Where
- 5 sites in China
- Volunteers
- 46 people
- Sponsor
- The First Affiliated Hospital of Zhengzhou University
Gastrointestinal Tumors, Solid Tumor
A Study of GNC-077 in Patients With Locally Advanced or Metastatic Gastrointestinal Tumors and Other Solid Tumors
This study is an open-label, multicenter, dose-escalation and cohort expansion phase I clinical study to evaluate the safety, tolerability, pharmacokinetics characteristics or preliminary efficacy and antitumor activity in…
- Trial name
- NCT06755242
- Testing
- GNC-077
- Where
- China
- Volunteers
- 20 people
- Sponsor
- Sichuan Baili Pharmaceutical Co., Ltd.
Esophagus Cancer
Neoadjuvant Immunotherapy Combined With Chemotherapy in Patients With Locally Advanced ESCC
Prediction for pCR After Neoadjuvant Immunotherapy Combined With Chemotherapy Using Single-Cell RNA Sequencing in Patients With Locally Advanced Esophageal Squamous Cell Carcinoma
- Trial name
- NCT05807542
- Testing
- Tislelizumab, Paclitaxel-albumin, Carboplatin
- Where
- China
- Volunteers
- 20 people
- Sponsor
- Shanghai Zhongshan Hospital
Advanced Solid Tumors
Safety and Efficacy Study of PRI-724 in Subjects With Advanced Solid Tumors
PRI-724 is a new investigational drug being studied to treat subjects with cancer who have advanced solid tumors. PRI-724 is thought to work by blocking the Wnt signaling pathway that cancer cells need to grow and…
- Trial name
- NCT01302405
- Testing
- PRI-724
- Where
- 3 sites in United States
- Volunteers
- 23 people
- Sponsor
- Prism Pharma Co., Ltd.
Pancreatic Ductal Adenocarcinoma
Pilot Phase 2 Study to Investigate the Preliminary Efficacy and Safety of INNO-206 in Advanced Pancreatic Cancer
Patients with metastatic, locally advanced, or unresectable pancreatic ductal carcinomas (PDA) who have failed prior chemotherapy with gemcitabine regimens have an extremely poor prognosis with progression-free survival of around…
- Trial name
- NCT01580397
- Testing
- INNO-206
- Where
- 6 sites in United States
- Volunteers
- 15 people
- Sponsor
- ImmunityBio, Inc.
Locally Advanced Rectal Cancer
Consolidation Versus Induction Chemotherapy in Total Neoadjuvant Therapy of Rectal Cancer With High Risk for Recurrence
The purpose of this study is to identify the most promising treatment sequence in total neoadjuvant therapy for locally advanced rectal cancer with a high risk of recurrence.
- Trial name
- ICONA (NCT05054959)
- Testing
- Consolidation CAPOX Chemotherapy, Induction CAPOX Chemotherapy
- Where
- Slovenia
- Volunteers
- 62 people
- Sponsor
- Institute of Oncology Ljubljana
Stomach Neoplasms
Biweekly Docetaxel in Combination With Capecitabine as First-Line Treatment in Patients With Advanced Gastric Cancer
To determine the quality of life in patients with gastric cancer who receive combination treatment with docetaxel and capecitabine. Secondary endpoints are time to progression, overall response rate and overall survival.
- Trial name
- GAST-TaxXel (NCT00669370)
- Testing
- docetaxel and capecitabine
- Where
- 6 sites in Finland
- Volunteers
- 50 people
- Sponsor
- University of Turku
Esophageal Squamous Cell Cancer, Adenocarcinoma of Esophagogastric Junction, Gastric Adenocarcinoma
Tucidinostat Plus PD-1 Inhibitor and Bevacizumab for Advanced Esophagus Cancer, AEG, Gastric Cancer
This Phase II study was designed to assess the efficacy and safety of the combination of PD-1 inhibitor, Tucidinostat (chidamide), a histone deacetylase inhibitor, and bevacizumab in advanced Esophageal squamous cell cancer…
- Trial name
- NCT05163483
- Testing
- Tucidinostat (chidamide), PD-1 inhibitor (Toripalimab), Bevacizumab
- Where
- China
- Volunteers
- 87 people
- Sponsor
- Ruihua Xu
Advanced Colorectal Carcinoma, Recurrent Colorectal Carcinoma
Molecular Study and Precision Medicine for Colorectal Cancer
Researchers collect specimens from advanced or recurrent colorectal cancer (CRC) patients to conduct molecular profiling and establish tumor organoids (PDOs)/ patient-derived xenografts (PDXs).
- Trial name
- MSPM (NCT05883683)
- Testing
- Molecular Profiling & drug testing in tumor organoids and PDXs
- Where
- China
- Volunteers
- 100 people
- Sponsor
- Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Gastric Cancer
SOX Combined With Tislelizumab and LDRT for Neoadjuvant Treatment of Locally Advanced Gastric Cancer
Neoadjuvant chemotherapy or chemoradiotherapy has become the standard neoadjuvant regimen for locally advanced G/GEJ cancer and has been recommended by a series of treatment guidelines.
- Trial name
- NCT06266871
- Testing
- SOX+Tislelizumab+LDRT
- Volunteers
- 64 people
- Sponsor
- West China Hospital
Potentially Resectable Locally Advanced Intrahepatic Cholangiocarcinoma and Gallbladder Cancer
Tislelizumab Combined With Lenvatinib and GEMOX Versus Tislelizumab Combined With GEMOX in Conversion Therapy of ICC and GBC.
This is an Open Phase II Clinical Study of Tislelizumab Combined with Lenvatinib and GEMOX Versus Tislelizumab Combined with GEMOX in the Treatment of Locally Advanced Intrahepatic Cholangiocarcinoma and Gallbladder Cancer.
- Trial name
- NCT05620498
- Testing
- tislelizumab+lenvatinib+GMOX, tislelizumab+GEMOX
- Where
- China
- Volunteers
- 60 people
- Sponsor
- Tianjin Medical University Cancer Institute and Hospital
Hepatocellular Carcinoma
TACE in Combination With PD-1/PD-L1 Inhibitors and Molecular Target Therapies for Advanced HCC
The purpose of this study is to evaluate the safety and efficacy of transarterial chemoembolization (TACE) in combination with immune checkpoint inhibitors (ICIs) and molecular target therapies in patients with advanced-stage…
- Trial name
- CHANCE2201 (NCT05332821)
- Testing
- PD-1/PD-L1 inhibitors+VEGF-TKI/bevacizumab, TACE
- Where
- 2 sites in China
- Volunteers
- 1,244 people
- Sponsor
- Zhongda Hospital
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.